Drug intelligence / Profile preview

RJ008

Development stage: Preclinical
Lead developer: Runjia
Modality: Small Molecules

Overview

RJ008 is a small molecule therapeutic candidate currently in the preclinical stage of development by Risen Shanghai Medical Technology (also known as Risen Pharma). It is being investigated for the treatment of various forms of cancer. As an early-stage asset within the company's oncology pipeline, the specific biological target and molecular mechanism of action for RJ008 have not yet been publicly disclosed. The program represents part of Risen Pharma's broader effort to develop innovative targeted therapies for high-unmet-need indications in oncology.

Beyond the preview

Go deeper on RJ008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ008.

Explore the full profile